*Note: For the investigational use of Adipose-Derived Stem Cells (ADSC’s) for clinical research and deployment.
CIDP also is known as chronic inflammatory demyelinating polyneuropathy is an auto-immune disease of the nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP is closely related to Guillan-Barre Disease. Treatment for CIDP includes steroids and immunosuppressant drugs. Plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIG) therapy also commonly used.
Aggressive treatment is often necessary to prevent the loss of axons and subsequent effects on the function or mobility of the patient. Some cases progress and are resistant to medical therapy, making it difficult to manage symptoms. There is hope that mesenchymal stem cells will mitigate some of the degenerative effects of CIDP neuropathy. Research is ongoing to evaluate the effects of stem cells on auto-immune conditions.
Stem Cells and CIDP
Regenerative Cell Medicine has developed a specific SVF deployment protocol that attempts to utilize the potential immune-modulatory and regenerative properties of SVF (rich in mesenchymal stem cells and growth factors). SVF is deployed systemically and may require repeat dosing. This is done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately three hours.
Stem cell therapy may provide new hope for patients with CIDP, mitigating the effects of chronic disease and the possibility of remission.